SEC Filing Summary: Sanofi (Form 13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Sanofi, an institutional investment manager based in Paris, France. The report covers the quarter ended March 31, 2026, and was signed on May 7, 2026, by Alexandra Roger, Head of Legal Corporate & Finance. The filing represents a holdings report for the manager's own accounts, with no other included managers.
Key Financial Metrics
As a Form 13F filing, this document discloses equity holdings rather than the company's operational financial performance. Consequently, data regarding Sanofi's revenue, profit, cash flow, margins, debt, or liquidity is not present in this text.
- Total Value of Reported Holdings: $335,959,156
- Total Number of Holdings Entries: 9
- Number of Other Included Managers: 0
Material Changes
The filing text does not provide comparative data against the prior period (December 31, 2025) to determine material changes in holdings or value. The document serves as a snapshot of holdings at the end of the reporting period.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies related to Sanofi's business operations. It strictly lists securities held by the manager.
Investor Verification Checklist
- Verify the specific 9 equity positions held by Sanofi as an investment manager, which are detailed in the schedules not included in this summary text.
- Confirm the total market value of these holdings ($335,959,156) against current market prices to assess potential valuation changes since the filing date.
- Note that this report reflects Sanofi's role as an investor in other companies, not its own corporate financial health.